EP0937095A4 - Targeted cytolysis of cancer cells - Google Patents

Targeted cytolysis of cancer cells

Info

Publication number
EP0937095A4
EP0937095A4 EP97911757A EP97911757A EP0937095A4 EP 0937095 A4 EP0937095 A4 EP 0937095A4 EP 97911757 A EP97911757 A EP 97911757A EP 97911757 A EP97911757 A EP 97911757A EP 0937095 A4 EP0937095 A4 EP 0937095A4
Authority
EP
European Patent Office
Prior art keywords
cancer cells
cytolysis
targeted
targeted cytolysis
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97911757A
Other languages
German (de)
French (fr)
Other versions
EP0937095A1 (en
Inventor
Gary B Greenburg
James G Mcarthur
Mitchell H Finer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Genesys Inc
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of EP0937095A1 publication Critical patent/EP0937095A1/en
Publication of EP0937095A4 publication Critical patent/EP0937095A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP97911757A 1996-10-25 1997-10-24 Targeted cytolysis of cancer cells Withdrawn EP0937095A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2902996P 1996-10-25 1996-10-25
US29029P 1996-10-25
PCT/US1997/018707 WO1998018809A1 (en) 1996-10-25 1997-10-24 Targeted cytolysis of cancer cells

Publications (2)

Publication Number Publication Date
EP0937095A1 EP0937095A1 (en) 1999-08-25
EP0937095A4 true EP0937095A4 (en) 1999-12-22

Family

ID=21846848

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97911757A Withdrawn EP0937095A4 (en) 1996-10-25 1997-10-24 Targeted cytolysis of cancer cells

Country Status (5)

Country Link
EP (1) EP0937095A4 (en)
JP (1) JP2002512502A (en)
AU (1) AU744160B2 (en)
CA (1) CA2269738A1 (en)
WO (1) WO1998018809A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
CA2382725A1 (en) * 1999-09-17 2001-03-22 Genzyme Transgenics Corporation Transgenically produced fusion proteins
EP1532162B1 (en) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
KR20120117931A (en) * 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. Methods for identifying and isolating cells expressing a polypeptide
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
CN104395344B (en) 2012-05-07 2019-08-13 达特茅斯大学理事会 Anti-B7-H6 antibodies, fusion proteins and methods of use thereof
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
ES2769574T3 (en) 2013-03-15 2020-06-26 Michael C Milone Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
EP3027755B1 (en) * 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
ES2918501T3 (en) 2013-12-19 2022-07-18 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
JP6831777B2 (en) 2014-07-21 2021-02-17 ノバルティス アーゲー Treatment of cancer using the CD33 chimeric antigen receptor
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
RU2751362C2 (en) 2014-12-29 2021-07-13 Новартис Аг Methods for producing cells expressing chimeric antigen receptor
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
PL3280729T3 (en) 2015-04-08 2022-08-22 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
JP6976960B2 (en) * 2015-11-27 2021-12-08 カーサリクス プロプライエタリー リミテッド Genetically modified cells and their use
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
PT3393504T (en) 2015-12-22 2025-12-30 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and anti-PD-L1 inhibitor antibody for combined use in anticancer therapy.
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
JP7467117B2 (en) 2016-10-07 2024-04-15 ノバルティス アーゲー Chimeric antigen receptors for the treatment of cancer - Patents.com
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
KR20190130608A (en) 2017-03-22 2019-11-22 노파르티스 아게 Compositions and Methods for Immune Oncology
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
AU2019225393A1 (en) * 2018-02-23 2020-08-20 Cartherics Pty. Ltd. T cell disease treatment targeting TAG-72
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag Bcma chimeric antigen receptors and uses thereof
SI3844267T1 (en) 2018-08-31 2025-10-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
JP7805928B2 (en) 2019-11-26 2026-01-26 ノバルティス アーゲー CD19 and CD22 chimeric antigen receptors and uses thereof
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359046A (en) * 1990-12-14 1994-10-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359046A (en) * 1990-12-14 1994-10-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ESHHAR ET AL: "SPECIFIC ACTIVATION AND TARGETING OF CYTOTOXIC LYMPHOCYTES THROUGH CHIMERIC SINGLE CHAINS CONSISTING OF ANTIBODY-BINDING DOMAINS AND THE GAMMA OR ZETA SUBUNITS OF THE IMMUNOGLOBULIN AND T-CELL RECEPTORS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, 1 January 1993 (1993-01-01), pages 720 - 724, XP002088319 *
HOMBACH A ET AL: "T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope.", GASTROENTEROLOGY, (1997 OCT) 113 (4) 1163-70. JOURNAL CODE: FH3. ISSN: 0016-5085., United States, XP002117237 *
HOMBACH, A. ET AL: "Expression of functional active chimeric T-cell receptors with antibody like specificity for the TAG72 tumor antigen.", ANNALS OF HEMATOLOGY, (1996) VOL. 73, NO. SUPPL. 2, PP. A152. MEETING INFO.: ANNUAL CONGRESS OF THE GERMAN AND THE AUSTRIAN SOCIETY OF HEMATOLOGY AND ONCOLOGY DUESSELDORF, GERMANY OCTOBER 3-7, 1996 ISSN: 0939-5555., XP002117385 *
MCARTHUR, J. G. (1) ET AL: "Targeting of tumor cells by T cells transduced with TAG-72 tumor antigen specific MHC-unrestricted chimeric T cell receptors.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (1997) VOL. 38, NO. 0, PP. 37. MEETING INFO.: EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH SAN DIEGO, CALIFORNIA, USA APRIL 12-16, 1997 ISSN:, XP002117386 *
MCGUINNESS R P ET AL: "Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor [see comments].", HUMAN GENE THERAPY, (1999 JAN 20) 10 (2) 165-73. JOURNAL CODE: A12. ISSN: 1043-0342., United States, XP002117239 *
MCGUINNESS, R. ET AL: "Targeting of tumor cells by T lymphocytes expressing tumor associated antigen specific, MHC-unrestricted chimeric T cell receptors.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (1997) VOL. 99, NO. 1 PART 2, PP. S41. MEETING INFO.: JOINT MEETING OF THE AM. ACAD. OF ALLERGY, ASTHMA AND IMMUNOL., THE AM. ASSOC. OF IMMUNOL. AND THE CLIN. IMMUNOL. SOC. SAN FRANSCISCO, FEBR. 21-26, 1997, XP002117387 *
SCHLOM, J. ET AL.: "Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates", CANCER RESEARCH, vol. 52, 1 March 1992 (1992-03-01), pages 1067 - 1072, XP002117238 *
See also references of WO9818809A1 *

Also Published As

Publication number Publication date
JP2002512502A (en) 2002-04-23
EP0937095A1 (en) 1999-08-25
AU4905897A (en) 1998-05-22
CA2269738A1 (en) 1998-05-07
WO1998018809A1 (en) 1998-05-07
AU744160B2 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
GB9622500D0 (en) Therapeutic gene
ZA972494B (en) Long wearing lipstick
EP0934404A4 (en) Inhibition of proliferation of cells
AU3583797A (en) Enhancement of cancer cell death
HUP9702242A3 (en) Inozitol-glykanes of inzulin-like activity
EP0972830A4 (en) Cancer-associated genes
AU6537798A (en) Targeted cytolysis of cancer cells
GB9602704D0 (en) Structure of perculator
GB9605453D0 (en) Cultured cells
IL129474A0 (en) Targeted cytotoxic cells
PL328829A1 (en) Enzyme
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
AU1801499A (en) Uses of p27 in prostate cancer
GB2333527B (en) Therapeutic gene
TW312301U (en) Improved structure of earmask
TW319017U (en) Improved structure of mousetraps
GB9713139D0 (en) Use of enzymes
GB9621289D0 (en) Pond
GB9617709D0 (en) Enzyme
GB9723412D0 (en) Cancer gene
TW309212U (en) Runner system of fuel cell
TW304520U (en) Improved structure of groyne
GB9727347D0 (en) Cancer
AP9600848A0 (en) Ther peuti amid s
TW301421U (en) Improved structure of rotaion-type calculator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990422

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991104

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20020910